



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/173

March 4, 2024

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. '**Biocon Biologics Secures Canada Market Entry Date for YESAFILI[®], a Proposed Biosimilar to EYLEA[®]**'.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics Secures Canada Market Entry Date for YESAFILI[®], a Proposed Biosimilar to EYLEA[®]

Bengaluru, Karnataka, India, March 4, 2024

Biocon Biologics Ltd (BBL), a globally integrated biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced the signing of a settlement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. This Agreement paves the way for the introduction of YESAFILI[®], a proposed biosimilar to EYLEA[®] (aflibercept) Injection, into the Canadian market.

Under the terms of the agreement, Biocon Biologics has secured a launch date for YESAFILI[®] 2 mg NDS for vials and prefilled syringes (yet to be filed), set no later than July 1, 2025. In March 2023, Health Canada had granted tentative approval for YESAFILI[®] 2 mg vials, subject to resolution of any patent issues.

The settlement resolves multiple parallel patent infringement proceedings in the Federal Court of Canada involving six patents, and associated judicial review proceedings, under Canada's *Patented Medicines (Notice of Compliance) Regulations* addressing pre-entry pharmaceutical patent litigation.

All trademarks, registered or unregistered, are the property of their respective owners.